Latest Breaking News On - Werner haas - Page 1 : comparemela.com

LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V

SCHLIEREN, Switzerland, February 22, 2024 LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants in low- and middle-income countries. In the nine-month-old target population, administration of S

United kingdomLimmatech biologicsAlexander siebertPatricia martinFranz werner haasNetwork meetingTrophic communicationsChief operating officerAnnual network meetingWellcome trustGram negative shigellaTech biologicsWerner haasClinical trialVaccine candidateDiarrheal disease

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Franz werner haasPaul wolfromAlexander siebertNicola forrestLimmatech biologicsSteve burnellStefan klotterTrophic communicationsImpact fundNovo holdingsAdjuvant capitalChief executive officerManaging directorChief financial officerTech biologicsWerner haas

Record-breaking aerodynamics in flying lawn chairs , Blue Whales, and Dolphins from NSU

Record-breaking aerodynamics in flying lawn chairs , Blue Whales, and Dolphins from NSU
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Baden wübergBonneville salt flatsUnited statesAudi mediacenterRupert hollausViktor frankenbergerWerner haasRennfox dolphinWilhelm herzRennmax dolphinKlaus arthKlasing verlagEdmund rumplerGustav adolf baummHermann paulPaul jaray

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc s Innovative Vaccine Candidate Against Staphylococcus aureus

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc s Innovative Vaccine Candidate Against Staphylococcus aureus
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomGretchen schweitzerJavad amanFranz werner haasLimmatech biologicsMichael kowarikNational institutes of healthBiomedical advanced researchDevelopment authorityImpact fundHuman servicesNational institute of allergyUs national institute of allergyGermany federal ministry of educationAdministration for strategic preparednessWorld health organization

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

SCHLIEREN, Switzerland, October 09, 2023 LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr

United statesNew yorkCity ofUnited kingdomAlexander siebertKabeer azizZina affas besseLimmatech biologicsFranz werner haasCamilla petrycer hansenHooft van huijsduijnenLimmatech bioNovo holdingPrincipal at novo holdingsImpact fundNational overview